CTLA4 and colorectal carcinoma: A more pronounced early PIV variation was also described by Corti et al.11 among those cases with non-mucinous CRC, and among those receiving dual PD-1/CTLA-4 blockade (instead of single-agent PD-1/PD-L1 blockade).